For nearly three decades Jack Lasersohn has put money into health care start-ups as an investor for Vertical Group and its predecessor F. Eberstadt & Co. Among his successful investments are Kyphon Inc., which went public in 2002, and E.P. Technologies Inc., which was acquired by Boston-Scientific Corp. in 1995 and pioneered the catheter-based treatment of cardiac arrhythmia.
As a board member for eight health-care companies, Lasersohn has closely followed Congress’ wrangling over health-care reform. We chatted with him today to get his thoughts on the new bill. Here’s an edited excerpt of that interview:
Q. What is your overall reaction to the health-care reform legislation?
There are going to be some positives. There will be more people insured, so there will be greater numbers of dollars flowing into the health-care system. There are things we applaud [such as] the follow-on biologics statute [calling for a 12-year data-exclusivity period for innovator biologics]. The venture capital industry fought very, very hard for a reasonable compromise for data exclusivity.
To read the full, original article click on this link: A Venture Capitalist’s Take On Health-Care Reform - Venture Capital Dispatch - WSJ
